These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 38071729)

  • 1. Sexual quality of life in patients with pemphigus: A case-control study.
    Maione V; Bettolini L; Cozzi C; Bighetti S; Tomasi C; Calzavara-Pinton P
    J Eur Acad Dermatol Venereol; 2024 Apr; 38(4):761-768. PubMed ID: 38071729
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Assessing the Correlation Between Disease Severity Indices and Quality of Life Measurement Tools in Pemphigus.
    Krain RL; Kushner CJ; Tarazi M; Gaffney RG; Yeguez AC; Zamalin DE; Pearson DR; Feng R; Payne AS; Werth VP
    Front Immunol; 2019; 10():2571. PubMed ID: 31781098
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Characteristics and quality of life in pemphigus patients.
    Tee CT; Lee CS; Gunabalasingam P
    Med J Malaysia; 2022 May; 77(3):324-330. PubMed ID: 35638489
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Quality-of-life assessment in patients with pemphigus using a minimum set of evaluation tools.
    Paradisi A; Sampogna F; Di Pietro C; Cianchini G; Didona B; Ferri R; Abeni D; Tabolli S
    J Am Acad Dermatol; 2009 Feb; 60(2):261-9. PubMed ID: 19004524
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Development of a quality-of-life instrument for autoimmune bullous disease: the Autoimmune Bullous Disease Quality of Life questionnaire.
    Sebaratnam DF; Hanna AM; Chee SN; Frew JW; Venugopal SS; Daniel BS; Martin LK; Rhodes LM; Tan JC; Wang CQ; Welsh B; Nijsten T; Murrell DF
    JAMA Dermatol; 2013 Oct; 149(10):1186-91. PubMed ID: 23925444
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Beyond the skin: disease parameters in pemphigus.
    Viti G; Forcella C; Feliciani C; Murrell DF
    Ital J Dermatol Venerol; 2021 Apr; 156(2):147-150. PubMed ID: 33960750
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Family impact of pemphigus disease in an Iranian population using the Family Dermatology Life Quality Index.
    Ghodsi SZ; Asadi A; Ghandi N; Balighi K; Mahmoudi H; Abedini R; Ghiasi M; Lajevardi V; Chams-Davatchi C; Daneshpazhooh M
    Int J Womens Dermatol; 2020 Dec; 6(5):409-413. PubMed ID: 33898709
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Quality of Life Assessment in Korean Patients with Pemphigus.
    Sung JY; Roh MR; Kim SC
    Ann Dermatol; 2015 Oct; 27(5):492-8. PubMed ID: 26512162
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Measuring of quality of life in autoimmune blistering disorders in Poland. Validation of disease - specific Autoimmune Bullous Disease Quality of Life (ABQOL) and the Treatment Autoimmune Bullous Disease Quality of Life (TABQOL) questionnaires.
    Kalinska-Bienias A; Jakubowska B; Kowalewski C; Murrell DF; Wozniak K
    Adv Med Sci; 2017 Mar; 62(1):92-96. PubMed ID: 28208086
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Quality of life and psychological status of patients with pemphigus vulgaris using Dermatology Life Quality Index and General Health Questionnaires.
    Ghodsi SZ; Chams-Davatchi C; Daneshpazhooh M; Valikhani M; Esmaili N
    J Dermatol; 2012 Feb; 39(2):141-4. PubMed ID: 21967321
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Outcome measures for autoimmune blistering diseases.
    Zhao CY; Murrell DF
    J Dermatol; 2015 Jan; 42(1):31-6. PubMed ID: 25558950
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Calculation of cut-off values based on the Autoimmune Bullous Skin Disorder Intensity Score (ABSIS) and Pemphigus Disease Area Index (PDAI) pemphigus scoring systems for defining moderate, significant and extensive types of pemphigus.
    Boulard C; Duvert Lehembre S; Picard-Dahan C; Kern JS; Zambruno G; Feliciani C; Marinovic B; Vabres P; Borradori L; Prost-Squarcioni C; Labeille B; Richard MA; Ingen-Housz-Oro S; Houivet E; Werth VP; Murrell DF; Hertl M; Benichou J; Joly P;
    Br J Dermatol; 2016 Jul; 175(1):142-9. PubMed ID: 26800395
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The health impact of pemphigus vulgaris and pemphigus foliaceus assessed using the Medical Outcomes Study 36-item short form health survey questionnaire.
    Tabolli S; Mozzetta A; Antinone V; Alfani S; Cianchini G; Abeni D
    Br J Dermatol; 2008 May; 158(5):1029-34. PubMed ID: 18294312
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Quality of life in patients with pemphigus receiving adjuvant therapy.
    Paradisi A; Cianchini G; Lupi F; Di Pietro C; Sampogna F; Didona B; Pagliarello C; Tabolli S; Abeni D
    Clin Exp Dermatol; 2012 Aug; 37(6):626-30. PubMed ID: 22816985
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pemphigus disease activity measurements: pemphigus disease area index, autoimmune bullous skin disorder intensity score, and pemphigus vulgaris activity score.
    Rahbar Z; Daneshpazhooh M; Mirshams-Shahshahani M; Esmaili N; Heidari K; Aghazadeh N; Hejazi P; Ghajarzadeh M; Chams-Davatchi C
    JAMA Dermatol; 2014 Mar; 150(3):266-72. PubMed ID: 24429657
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Large International Validation of ABSIS and PDAI Pemphigus Severity Scores.
    Hébert V; Boulard C; Houivet E; Duvert Lehembre S; Borradori L; Della Torre R; Feliciani C; Fania L; Zambruno G; Camaioni DB; Didona B; Marinovic B; Schmidt E; Schumacher N; Hünefeld C; Schanz S; Kern JS; Hofmann S; Bouyeure AC; Picard-Dahan C; Prost-Squarcioni C; Caux F; Alexandre M; Ingen-Housz-Oro S; Bagot M; Tancrede-Bohin E; Bouaziz JD; Franck N; Vabres P; Labeille B; Richard MA; Delaporte E; Dupuy A; D'Incan M; Quereux G; Skowro F; Paul C; Livideanu CB; Beylot-Barry M; Doutre MS; Avenel-Audran M; Bedane C; Bernard P; Machet L; Maillard H; Jullien D; Debarbieux S; Sassolas B; Misery L; Abasq C; Dereure O; Lagoutte P; Ferranti V; Werth VP; Murrell DF; Hertl M; Benichou J; Joly P; ;
    J Invest Dermatol; 2019 Jan; 139(1):31-37. PubMed ID: 30301637
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Skin-Related Quality of Life During Autoimmune Bullous Disease Course.
    Hopkins ZH; Jimenez A; Taliercio VL; Clarke JT; Hansen CB; Hull CM; Rhoads JLW; Zone JJ; Sahni VN; Kean J; Secrest AM
    JAMA Dermatol; 2023 Nov; 159(11):1185-1194. PubMed ID: 37703003
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Grading criteria for disease severity by pemphigus disease area index.
    Shimizu T; Takebayashi T; Sato Y; Niizeki H; Aoyama Y; Kitajima Y; Iwatsuki K; Hashimoto T; Yamagami J; Werth VP; Amagai M; Tanikawa A
    J Dermatol; 2014 Nov; 41(11):969-73. PubMed ID: 25346300
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effect of autoimmune blistering diseases on work productivity.
    Wang EQ; Radjenovic M; Castrillón MA; Feng GHY; Murrell DF
    J Eur Acad Dermatol Venereol; 2018 Nov; 32(11):1959-1966. PubMed ID: 29730897
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The sexuality and quality of life of hemodialyzed patients--ASED multicenter study.
    Lew-Starowicz M; Gellert R
    J Sex Med; 2009 Apr; 6(4):1062-1071. PubMed ID: 19175866
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.